Last reviewed · How we verify

NCT05189990

Electrical Impedance Tomography in Fatty Liver Detection

Completed Last updated 8 May 2024
What this trial tests

trial testing Electrical impedance tomography in Non-Alcoholic Fatty Liver Disease in 160 participants. Completed in 29 February 2024.

Timeline
1 January 2022
Primary endpoint
29 February 2024
29 February 2024

Quick facts

Lead sponsorThe University of Hong Kong
StatusCompleted
Study typeOBSERVATIONAL
Enrollment160
Start date1 January 2022
Primary completion29 February 2024
Estimated completion29 February 2024
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

The University of Hong Kong

Who can join

Adults 20 to 75, any sex, with Non-Alcoholic Fatty Liver Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Non-alcoholic fatty liver disease (NAFLD) is a condition where hepatocytes contain an abnormally high fat percentage. This condition is becoming increasingly common due to unhealthy food habits and sedentary lifestyle. Since NAFLD is a silent disease, many patients would be diagnosed at the advanced stages when fat accumulation, scarring and liver cell damage are irreversible. Therefore, early diagnosis of fatty liver disease during its reversible stages is warranted. Current diagnostic techniques for fatty liver disease, such as the FibroScan® and MRI proton density fat fraction (PDFF) are expensive, and require the active work of certified professionals. Electrical Impedance Tomography (EIT) is an alternative low cost, non-invasive imaging technique that does not involve radiation nor a trained operator. The electrical conductivity of biological tissues varies according to the tissue type and frequency of AC current. Fat tissue conductivity is known to be substantially stable across the EIT current injection frequency spectrum. On the other hand, liver tissue conductivity significantly increases over frequency change. Hence, the liver fat content can be measured using frequency-difference EIT (fdEIT). The aim of this study is to investigate the feasibility and effectiveness of fdEIT in detecting fatty liver. To achieve this goal, a total of 160 subjects will be recruited, paired fdEIT-Fibroscan data will be acquired. First, optimal fdEIT current injection frequency range will be determined. Second, fdEIT derived indicators will be computed and statistical analysis will be performed to verify the significance of correlation between the two. Comparative exploration between EIT and MRI-PDFF will be performed on a subset of the study population, looking at both spatial localization and image derived indicators. Finally, demographics, clinical assessment and patient history will be analysed to produce demographic group-based insights.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Electrical impedance tomography

Trials testing the same drug.

Other recruiting trials for Non-Alcoholic Fatty Liver Disease

Currently open trials in the same condition.

Other The University of Hong Kong trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05189990.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing